Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 777

1.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.

Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.

PMID:
31307535
Free Article
2.

On using machine learning algorithms to define clinically meaningful patient subgroups.

Knevel R, Huizinga TW.

Ann Rheum Dis. 2019 Jul 11. pii: annrheumdis-2019-215959. doi: 10.1136/annrheumdis-2019-215959. [Epub ahead of print] No abstract available.

PMID:
31296500
3.

Treat-to-Target Strategies in Rheumatoid Arthritis.

van der Hem-van Mil AHM, Huizinga TWJ, Bloem JL.

JAMA. 2019 Jul 2;322(1):83. doi: 10.1001/jama.2019.5848. No abstract available.

PMID:
31265094
4.

Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening.

van Leeuwen NM, Boonstra M, Marsan NA, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK.

J Rheumatol. 2019 Jul 1. pii: jrheum.181378. doi: 10.3899/jrheum.181378. [Epub ahead of print]

PMID:
31263069
5.

Performance of the proposed ACR-EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms.

Gegenava M, Beaart HJL, Monahan RC, Brilman E, Beaart-van de Voorde LJJ, Magro-Checa C, Huizinga TWJ, Steup-Beekman GM.

RMD Open. 2019 Jun 5;5(1):e000895. doi: 10.1136/rmdopen-2019-000895. eCollection 2019. No abstract available.

6.

Men Have a Stronger Monocyte-Derived Cytokine Production Response upon Stimulation with the Gram-Negative Stimulus Lipopolysaccharide than Women: A Pooled Analysis Including 15 Study Populations.

Beenakker KGM, Westendorp RGJ, de Craen AJM, Chen S, Raz Y, Ballieux BEPB, Nelissen RGHH, Later AFL, Huizinga TW, Slagboom PE, Boomsma DI, Maier AB.

J Innate Immun. 2019 Jun 21:1-12. doi: 10.1159/000499840. [Epub ahead of print]

7.

Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA.

Matthijssen XM, Huizinga TW, Niemantsverdriet E, van der Helm-van Mil AH.

Ann Rheum Dis. 2019 Jun 22. pii: annrheumdis-2019-215843. doi: 10.1136/annrheumdis-2019-215843. [Epub ahead of print] No abstract available.

PMID:
31229951
8.

OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis.

Takata M, Pachera E, Frank-Bertoncelj M, Kozlova A, Jüngel A, Whitfield ML, Assassi S, Calcagni M, de Vries-Bouwstra J, Huizinga TW, Kurreeman F, Kania G, Distler O.

Front Immunol. 2019 May 17;10:1100. doi: 10.3389/fimmu.2019.01100. eCollection 2019.

9.

Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification.

Kampstra ASB, Dekkers JS, Volkov M, Dorjée AL, Hafkenscheid L, Kempers AC, van Delft M, Kissel T, Reijm S, Janssen GMC, van Veelen PA, Bang H, Huizinga TWJ, Trouw LA, van der Woude D, Toes REM.

Ann Rheum Dis. 2019 Jul;78(7):908-916. doi: 10.1136/annrheumdis-2018-214950. Epub 2019 May 31.

PMID:
31151934
10.

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.

Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM.

Arthritis Res Ther. 2019 May 14;21(1):121. doi: 10.1186/s13075-019-1902-2.

11.

N-linked glycans in the variable domain of ACPA-IgG predict the development of rheumatoid arthritis.

Hafkenscheid L, de Moel E, Smolik I, Tanner S, Meng X, Jansen BC, Bondt A, Wuhrer M, Huizinga TWJ, Toes REM, El-Gabalawy H, Scherer HU.

Arthritis Rheumatol. 2019 May 8. doi: 10.1002/art.40920. [Epub ahead of print]

PMID:
31067000
12.
13.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

14.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

15.

Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Chadli L, Sotthewes B, Li K, Andersen SN, Cahir-McFarland E, Cheung M, Cullen P, Dorjée A, de Vries-Bouwstra JK, Huizinga TWJ, Fischer DF, DeGroot J, Viney JL, Zheng TS, Aarbiou J, Gardet A.

Sci Rep. 2019 Mar 14;9(1):4521. doi: 10.1038/s41598-019-41153-w.

16.

Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study.

van Wijngaarden SE, Ben Said-Bouyeri S, Ninaber MK, Huizinga TWJ, Schalij MJ, Bax JJ, Delgado V, de Vries-Bouwstra JK, Marsan NA.

J Rheumatol. 2019 Apr;46(4):405-415. doi: 10.3899/jrheum.171207. Epub 2019 Mar 1.

PMID:
30824646
17.

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.

Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Flake Ii DD, Sasso EH, Huizinga TW.

Curr Med Res Opin. 2019 Mar 14:1-11. doi: 10.1080/03007995.2019.1585064. [Epub ahead of print]

PMID:
30777458
18.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

19.

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Boonstra M, Ninaber MK, Ajmone Marsan N, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2019 Apr 1;58(4):730-732. doi: 10.1093/rheumatology/kez005. No abstract available.

PMID:
30690619
20.

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2019 Jan 18;21(1):28. doi: 10.1186/s13075-019-1815-0.

21.

Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go?

Magro-Checa C, Steup-Beekman GM, Huizinga TW, van Buchem MA, Ronen I.

Front Med (Lausanne). 2018 Dec 4;5:340. doi: 10.3389/fmed.2018.00340. eCollection 2018. Review.

22.

Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.

Magro-Checa C, Kumar S, Ramiro S, Beaart-van de Voorde LJ, Eikenboom J, Ronen I, de Bresser J, van Buchem MA, Huizinga TW, Steup-Beekman GM.

Lupus. 2019 Jan;28(1):94-103. doi: 10.1177/0961203318816819. Epub 2018 Dec 8.

23.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D.

Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13.

PMID:
30425107
24.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

25.

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, Kroon FPB, Punzi L, Smolen JS, Vander Cruyssen B, Wolterbeek R, Verbruggen G, Wittoek R.

Ann Rheum Dis. 2018 Dec;77(12):1757-1764. doi: 10.1136/annrheumdis-2018-213202. Epub 2018 Oct 3.

PMID:
30282670
26.

Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis.

Dekkers JS, Bergstra SA, Chopra A, Tikly M, Fonseca JE, Salomon-Escoto K, Huizinga TWJ, van der Woude D.

Rheumatology (Oxford). 2019 Jan 1;58(1):149-153. doi: 10.1093/rheumatology/key263.

PMID:
30204896
27.

To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?

Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, Scherer HU, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):109-117. Epub 2018 Jul 18.

PMID:
30148428
28.

Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al.

Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helm-van Mil AHM, Knevel R, Westerlind H, Saevarsdottir S, Ajeganova S, van der Woude D.

Arthritis Rheumatol. 2018 Dec;70(12):2096-2097. doi: 10.1002/art.40678. Epub 2018 Oct 27. No abstract available.

PMID:
30058116
29.

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Goekoop-Ruiterman YPM, Steup-Beekman GM, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Ann Rheum Dis. 2018 Dec;77(12):1836-1838. doi: 10.1136/annrheumdis-2018-213823. Epub 2018 Jul 25. No abstract available.

PMID:
30045852
30.

MR signal intensity: staying on the bright side in MR image interpretation.

Bloem JL, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM.

RMD Open. 2018 Jun 20;4(1):e000728. doi: 10.1136/rmdopen-2018-000728. eCollection 2018.

31.

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.

Akdemir G, Markusse IM, Bergstra SA, Goekoop RJ, Molenaar ET, van Groenendael JHLM, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF.

RMD Open. 2018 May 20;4(1):e000649. doi: 10.1136/rmdopen-2018-000649. eCollection 2018.

32.

The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching.

van Delft MAM, Verheul MK, Burgers LE, Rantapää-Dahlqvist S, van der Helm-van Mil AHM, Huizinga TWJ, Toes REM, Trouw LA.

Rheumatology (Oxford). 2018 Sep 1;57(9):1583-1591. doi: 10.1093/rheumatology/key135.

PMID:
29846726
33.

Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.

Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, Westra J, Brink M, Rantapää-Dahlqvist S, Huizinga TWJ, van der Helm-van Mil AHM, van der Woude D, Toes REM, Trouw LA.

Arthritis Rheumatol. 2018 Nov;70(11):1721-1731. doi: 10.1002/art.40562. Epub 2018 Sep 16.

PMID:
29781231
34.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators.

Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121.

35.

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.

Jansen DTSL, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE, Ye J, Toes REM, Huizinga TWJ.

RMD Open. 2018 Mar 30;4(1):e000564. doi: 10.1136/rmdopen-2017-000564. eCollection 2018.

36.

Comment on "Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis".

Volkov M, Dekkers J, Loos BG, Bizzarro S, Huizinga TWJ, Praetorius HA, Toes REM, van der Woude D.

Sci Transl Med. 2018 Mar 21;10(433). pii: eaan8349. doi: 10.1126/scitranslmed.aan8349.

PMID:
29563322
37.

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.

de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2018 Feb 26;20(1):33. doi: 10.1186/s13075-018-1520-4.

38.

The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Scherer HU, Huizinga TWJ, Krönke G, Schett G, Toes REM.

Nat Rev Rheumatol. 2018 Mar;14(3):157-169. doi: 10.1038/nrrheum.2018.10. Epub 2018 Feb 8. Review.

PMID:
29416134
39.

Fc gamma receptor binding profile of anti-citrullinated protein antibodies in immune complexes suggests a role for FcγRI in the pathogenesis of synovial inflammation.

Kempers AC, Nejadnik MR, Rombouts Y, Ioan-Facsinay A, van Oosterhout M, Jiskoot W, Huizinga TWJ, Toes REM, Scherer HU.

Clin Exp Rheumatol. 2018 Mar-Apr;36(2):284-293. Epub 2018 Jan 15.

40.

Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis.

Boer AC, Huizinga TWJ, van der Helm-van Mil AHM.

Ann Rheum Dis. 2019 Jan;78(1):e1. doi: 10.1136/annrheumdis-2017-212867. Epub 2018 Jan 8. No abstract available.

41.

Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents.

Bergstra SA, Chopra A, Saluja M, Vega-Morales D, Govind N, Huizinga TWJ, van der Helm-van Mil A.

RMD Open. 2017 Dec 10;3(2):e000568. doi: 10.1136/rmdopen-2017-000568. eCollection 2017.

42.

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K.

Rheumatology (Oxford). 2018 Mar 1;57(3):589. doi: 10.1093/rheumatology/kex503. No abstract available.

43.

Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis.

Messemaker TC, Chadli L, Cai G, Goelela VS, Boonstra M, Dorjée AL, Andersen SN, Mikkers HMM, van 't Hof P, Mei H, Distler O, Draisma HHM, Johnson ME, Orzechowski NM, Simms RW, Toes REM, Aarbiou J, Huizinga TW, Whitfield ML, DeGroot J, de Vries-Bouwstra J, Kurreeman F.

J Invest Dermatol. 2018 Apr;138(4):826-835. doi: 10.1016/j.jid.2017.09.053. Epub 2017 Nov 24.

44.

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.

Bergstra SA, Allaart CF, van den Berg R, Chopra A, Govind N, Huizinga TWJ, Landewe RBM.

Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.

45.

An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus.

Teng YKO, Bredewold EOW, Rabelink TJ, Huizinga TWJ, Eikenboom HCJ, Limper M, Fritsch-Stork RDE, Bloemenkamp KWM, Sueters M.

Rheumatology (Oxford). 2018 Oct 1;57(10):1707-1720. doi: 10.1093/rheumatology/kex374. Review.

PMID:
29165607
46.

Preventing progression from arthralgia to arthritis: targeting the right patients.

van Steenbergen HW, da Silva JAP, Huizinga TWJ, van der Helm-van Mil AHM.

Nat Rev Rheumatol. 2018 Jan;14(1):32-41. doi: 10.1038/nrrheum.2017.185. Epub 2017 Nov 9. Review.

47.

Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.

Akdemir G, Heimans L, Bergstra SA, Goekoop RJ, van Oosterhout M, van Groenendael JHLM, Peeters AJ, Steup-Beekman GM, Lard LR, de Sonnaville PBJ, Grillet BAM, Huizinga TWJ, Allaart CF.

Ann Rheum Dis. 2018 Jan;77(1):111-118. doi: 10.1136/annrheumdis-2017-211375. Epub 2017 Sep 28.

PMID:
28970207
48.

Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.

Bergstra SA, Landewé RBM, Huizinga TWJ, Allaart CF.

Rheumatology (Oxford). 2017 Oct 1;56(10):1721-1728. doi: 10.1093/rheumatology/kex236.

PMID:
28957556
49.

Using a reference when defining an abnormal MRI reduces false-positive MRI results-a longitudinal study in two cohorts at risk for rheumatoid arthritis.

Boer AC, Burgers LE, Mangnus L, Ten Brinck RM, Nieuwenhuis WP, van Steenbergen HW, Reijnierse M, Huizinga TWJ, van der Helm van Mil AHM.

Rheumatology (Oxford). 2017 Oct 1;56(10):1700-1706. doi: 10.1093/rheumatology/kex235.

PMID:
28957551
50.

Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort.

Damman W, Liu R, Kroon FPB, Reijnierse M, Huizinga TWJ, Rosendaal FR, Kloppenburg M.

J Rheumatol. 2017 Nov;44(11):1659-1666. doi: 10.3899/jrheum.170208. Epub 2017 Sep 15. Erratum in: J Rheumatol. 2019 Jan;46(1):118-119.

PMID:
28916548

Supplemental Content

Loading ...
Support Center